Accessibility Menu
Profound Medical logo

Profound Medical(TSX) PRN

Market CapCA$344.50MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2015)-37%
5 Year-51%
1 Year+56%
1 Month-20%
CA$9.44
+0.11%
+0.01Today
Profound Medical last closing stock price
MetricPriceDate
Last closeCAD 9.442026-09-03
Profound Medical stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-2.07%CAD 9.642026-08-27
1 month-19.73%CAD 11.762026-08-04
3 month+1.07%CAD 9.342026-06-05
Year to date-12.35%CAD 10.772025-12-31
1 year+55.52%CAD 6.072025-09-03
3 year-24.78%CAD 12.552023-09-01
5 year-51.44%CAD 19.442021-09-03
Since inception-37.13%CAD 15.002015-06-09

Profound Medical Financials at a Glance

Market Cap

CA$344.50MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$18.97M

Net Income (TTM)

-$32.42M

EPS (TTM)

-CA$1.37

P/E Ratio

-6.90

Dividend

CA$0.00

Beta (Volatility)

1.04 (Average)

Price

CA$9.44

Volume

7,757

Open

CA$9.52

Previous Close

CA$9.44

Daily Range

CA$9.39 - CA$9.53

52-Week Range

CA$5.23 - CA$12.40

Estimated Earnings Date

Nov 12, 2026

PRN News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Profound Medical

Profound Medical Corp. is a commercial-stage medical technology firm specializing in innovative magnetic resonance (MR) guided ablation therapies. The company focuses on addressing prostate conditions, uterine fibroids, and providing palliative pain management solutions.

Products and Services
  • TULSA-PRO system for prostate treatment
  • Sonalleve platform for uterine fibroids and pain management
  • Integration with MRI scanners for enhanced treatment accuracy
Growth Outlook
  • Expansion into new markets, including Canada, Germany, and the U.S.
  • Increasing demand for non-invasive treatment options
  • Focus on research and development to enhance product offerings
Financial Highlights
  • Q2 2026 revenue of 2.42 million, showing a strategic growth trajectory
  • Cash reserves of 38.21 million, providing operational stability
  • Current ratio of 6.46, indicating strong liquidity position
Profound Medical Corp. operates in the healthcare sector, specifically within the medical devices industry. The company's flagship products, the TULSA-PRO and Sonalleve systems, are designed to provide effective and non-invasive treatment options for patients. The focus on MR-guided therapies positions the company well in a growing market that increasingly favors minimally invasive procedures. The growth outlook for Profound Medical is promising, with plans to expand into new geographical markets and a commitment to research and development. This strategic direction aims to meet the rising demand for innovative medical solutions, particularly in the treatment of prostate conditions and uterine fibroids. Financially, the company has demonstrated resilience, with a notable revenue of 2.42 million in the second quarter of 2026. The strong cash reserves of 38.21 million provide a solid foundation for ongoing operations and future growth initiatives. Additionally, a current ratio of 6.46 reflects a robust liquidity position, allowing the company to meet its short-term obligations effectively. Overall, Profound Medical Corp. presents a compelling opportunity for investors interested in the medical technology sector, particularly those focused on innovative treatment solutions.
AI Generated • Aug 20, 2026

Industry

Healthcare Equipment and Supplies

Sector

Health Care

Employees

162

CEO

Arun S. Menawat, PhD, EMBA

Website

www.profoundmedical.com

Headquarters

Mississauga, ON L4W 5K5, CA

PRN Financials

Key Financial Metrics (TTM)

Gross Margin

71.73%

Operating Margin

-184.35%

Net Income Margin

-170.92%

Return on Equity

-62.45%

Return on Capital

-59.11%

Return on Assets

-52.05%

Earnings Yield

-14.49%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

CA$344.50MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

36.53M

Volume

7.76K

Avg. Volume

13.55K

Financials (TTM)

Gross Profit

$13.61M

Operating Income

-$34.97M

EBITDA

-$33.44M

Operating Cash Flow

-$35.61M

Capital Expenditure

-$179.09K

Free Cash Flow

-$35.79M

Cash & ST Invst.

$38.21M

Total Debt

$7.37M

Profound Medical Performance Analysis

Profound Medical annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 8,697,6830.9%
20232023-12-31USD 9,716,39611.7%
20242024-12-31USD 14,631,19050.6%
20252025-12-31USD 22,493,55153.7%
Profound Medical sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30136.6%
Q42025-12-3116.0%
Q12026-03-31-13.5%
Q22026-06-30-53.9%
Profound Medical annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -1.79-4.7%
20232023-12-31USD -1.800.7%
20242024-12-31USD -1.54-14.7%
20252025-12-31USD -1.9727.9%
Profound Medical sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3050.0%
Q42025-12-31-3.8%
Q12026-03-3129.6%
Q22026-06-30-31.6%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$2.42M

+9.4%

Gross Profit

$1.90M

+17.2%

Gross Margin

78.41%

N/A

Market Cap

CA$344.50MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

CA$2.13M

N/A

Employees

162

N/A

Net Income

-$9.29M

+40.8%

EBITDA

-$10.65M

+22.1%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$38.21M

+8.6%

Total Debt

$7.37M

+53.1%

Accounts Receivable

$9.60M

+96.0%

Inventory

$10.44M

+25.0%

Long Term Debt

$2.75M

-39.4%

Short Term Debt

$4.62M

+728.6%

Return on Assets

-52.05%

N/A

Return on Invested Capital

-65.74%

N/A

Free Cash Flow

-$11.03M

+19.7%

Operating Cash Flow

-$11.03M

+19.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
XLY.TOAuxly Cannabis Group Inc.
CA$3.17+1.28%
NGEN.VNervGen Pharma Corp.
CA$5.15+3.00%
DR.TOMedical Facilities Corporation
CA$15.27+0.66%
CRRX.TOCareRx Corporation
CA$3.27+3.15%

Trending Stocks

Symbol / CompanyPricePrice Chg
NOKNokia
$9.77-0.01%
HPEHewlett Packard Enterprise
$54.44+0.05%
FFord Motor Company
$14.41+0.02%
SNAPSnap
$5.70+0.02%

Questions About PRN

What is the current price of Profound Medical?

Profound Medical is trading at CA$9.44 per share.

What is the 52-week range for Profound Medical?

Over the past 52 weeks, Profound Medical has traded between CA$5.23 and CA$12.40.

How much debt does Profound Medical have?

As of the most recent reporting period, Profound Medical reported total debt of $10.47M.

How much cash does Profound Medical have on hand?

Profound Medical reported $54.30M in cash and cash equivalents in its most recent financial results.

What is Profound Medical’s dividend yield?

Profound Medical does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services